Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spartalizumab in Refractory Esophageal Squamous Cell Carcinoma
NCT03785496Phase 2Unknown
- Sponsor
- Yonsei University
- Start
- Feb 2020
- Primary completion
- Jan 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of spartalizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Yonsei University. Status: unknown.
02
Drugs
spartalizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03785496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03785496.